STAMPEDE2 Comparison P - FAQs for Patients

What is Comparison P in STAMPEDE2?

The STAMPEDE2 Comparison P study (also called STAMPEDE2-P) combines ¹⁷⁷Lu-PSMA-617 with Standard of Care (androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), with the possible addition of radiotherapy to the prostate primary (RT) and docetaxel chemotherapy). STAMPEDE2 aims to find out if this combination is safe and effective as a treatment for people with metastatic hormone sensitive prostate cancer (mHSPC).

A combination of ADT and ARPI treatment (with RT and Docetaxel in selected patients) is considered part of the standard of care (SOC) for patients diagnosed with metastatic prostate cancer or those who have developed metastases after prior treatment of localised prostate cancer.

What do I need to know about ¹⁷⁷Lu-PSMA-617?

¹⁷⁷Lu-PSMA-617 is an injectable therapy that directly kills cancer cells through radiation.  It achieves targeted treatment to the cancer cells because once injected, it finds its way only to cells which display a protein called prostate specific membrane antigens (PSMA). PSMA is overproduced in prostate cancer cells.  Lutetium-177 (which is the ‘¹⁷⁷Lu’ part of ¹⁷⁷Lu-PSMA-617) is what delivers the radiation to the prostate cancer cells. The amount of radiation is carefully selected to deliver damage and resulting death of the cancer cells whilst minimising damage to healthy tissue because the radiation emitted only travels a short distance. In 2022, ¹⁷⁷Lu-PSMA-617 was approved by the Medicines and Healthcare Regulatory Agency (MHRA) for use in people with metastatic prostate cancer that has become resistant to hormone treatments, also known as castrate resistant prostate cancer (CRPC).

It is not yet known whether additional treatment with ¹⁷⁷Lu-PSMA-617 alongside standard of care in people with metastatic prostate cancer before it becomes resistant to treatment is as safe or more effective at treating the prostate cancer than standard of care treatments. This study will help answer these questions.

Further information

For more FAQs and answers related to the STAMPEDE2 Comparison P study, please find the Comparison P Patient Information Sheet (PIS) here:

STAMPEDE2 Comparison P PIS V7.0

The Comparison P PIS contains further material on ¹⁷⁷Lu-PSMA-617, screening assessments, possible side effects, and more information on taking part in STAMPEDE2.